Capital One Initiates Coverage On Protagonist Therapeutics with Overweight Rating
Protagonist Therapeutics, Inc. +0.53%
Protagonist Therapeutics, Inc. PTGX | 39.51 | +0.53% |
Capital One analyst Tim Chiang initiates coverage on Protagonist Therapeutics (NASDAQ:
PTGX) with a Overweight rating.